In all trials, SGLT2 inhibitors were compared with placebo administered on top of standard background therapy, which generally included guideline-directed treatments for diabetes and cardiovascular risk reduction (e.g., metformin, statins, ACE inhibitors/ARBs, and antiplatelet therapy, as applicable). The gene discussed is SLC5A2; the disease is diabetes mellitus.